Genetic signatures for colon cancer
23 Jul 2012
Genetic signatures for colon cancer
Colorectal cancer in the elderly
The EUREKA Initiative
Prevention best ‘treatment’ for colon cancer
Bevacizumab benefits beyond progression in TML study subgroups
Pharmacodynamic endpoints need to be included in GI trials
Exploring new targets in GI cancer
Unravelling mechanisms of resistance to targeted drugs
CORRECT study data prompts US FDA priority review
Anti-angiogenic trials; key highlights of the 14th WCGC
Epigenetics of cancer and changes in DNA modification in tumours
Perifosine disappoints in refractory mCRC